Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 4Cetuximab 4pembrolizumab 3Radiotherapy 3cemiplimab 2Surveys and Questionnaires 2Magnetic Resonance Spectroscopy 2Carboplatin 2olaparib 1niraparib 1fludarabine 1dostarlimab 1calcipotriene 1avelumab 1atezolizumab 1alpha-2'-deoxythioguanosine 1aldesleukin 1Watchful Waiting 1Tiragolumab 1Surgical Procedures, Operative 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiosurgery 1Platinum 1Phlebotomy 1Paclitaxel 1Nivolumab 1Lidocaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × Atorvastatin × 30 days × Clear all
NCT04915183 2026-06-03

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Recruiting
224 enrolled
Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡